Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA yield high or low?
The EBITDA yield of 0.01% is in line with its estimated 1-year average of 0.01%, around the middle of its estimated 1-year range (0.01%–0.01%).
As of 2026-10-06T13:30:58.219Z.
Calculation as of: 2026-10-06T13:30:58.219Z.
Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9f8c720c17565e189db9218018d8859aabec9e8167d5f057fd0cc602bb9808d0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
0.01%
EBITDA YIELD AVG TTM
N/A
EBITDA YIELD AVG 3Y
N/A
EBITDA YIELD AVG 5Y
N/A
EBITDA YIELD AVG 10Y
N/A
EBITDA YIELD AVG 15Y
N/A
EBITDA YIELD AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
6.40%
median of 163 covered companies
CURRENT VS SECTOR MEDIAN
-99.84%
vs the sector median at left
Market Cap
$484.56M
EBITDA Yield
N/A
TTM Avg
25.96%
3Y Avg
19.61%
5Y Avg
19.61%
Market Cap
$488.09M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$458.01M
EBITDA Yield
N/A
TTM Avg
8.61%
3Y Avg
13.81%
5Y Avg
19.64%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cerus Corporation (CERS) | $477.61M | 0.01% | N/A | N/A | N/A |
| Arvinas, Inc. (ARVN)vs › | $483.26M | N/A | N/A | N/A | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $484.56M | N/A | 25.96% | 19.61% | 19.61% |
| NRC Health (NRC)vs › | $470.12M | 4.20% | 6.53% | 7.37% | 6.54% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $488.09M | N/A | N/A | N/A | N/A |
| Kamada Ltd. (KMDA)vs › | $465.02M | 9.64% | 10.23% | 10.38% | 8.34% |
| Evolus, Inc. (EOLS)vs › | $491.93M | N/A | N/A | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $458.01M | N/A | 8.61% | 13.81% | 19.64% |
| Assembly Biosciences, Inc. (ASMB)vs › | $452.63M | N/A | N/A | N/A | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $445.71M | 225.88% | 150.45% | 150.45% | 150.45% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA YIELD |
|---|---|
| 2026-10-05 | 0.01% |
| 2026-10-02 | 0.01% |
| 2026-10-01 | 0.01% |
| 2026-09-30 | 0.01% |
| 2026-09-29 | 0.01% |
| 2026-09-28 | 0.01% |
| 2026-09-25 | 0.01% |
| 2026-09-24 | 0.01% |
| 2026-09-23 | 0.01% |
| 2026-09-22 | 0.01% |
| 2026-09-21 | 0.01% |
| 2026-09-18 | 0.01% |
| 2026-09-17 | 0.01% |
| 2026-09-16 | 0.01% |
| 2026-09-15 | 0.01% |
| 2026-09-14 | 0.01% |
| 2026-09-11 | 0.01% |
| 2026-09-10 | 0.01% |
| 2026-09-09 | 0.01% |
| 2026-09-08 | 0.01% |
| 2026-09-04 | 0.01% |
| 2026-09-03 | 0.01% |
| 2026-09-02 | 0.01% |
| 2026-09-01 | 0.01% |
| 2026-08-31 | 0.01% |
| 2026-08-28 | 0.01% |
| 2026-08-27 | 0.01% |
| 2026-08-26 | 0.01% |
| 2026-08-25 | 0.01% |
| 2026-08-24 | 0.01% |
| 2026-08-21 | 0.01% |
| 2026-08-20 | 0.01% |
| 2026-08-19 | 0.01% |
| 2026-08-18 | 0.01% |
| 2026-08-17 | 0.01% |
| 2026-08-14 | 0.01% |
| 2026-08-13 | 0.01% |
| 2026-08-12 | 0.01% |
| 2026-08-11 | 0.01% |
| 2026-08-10 | 0.01% |
| 2026-08-07 | 0.01% |
| 2026-08-06 | 0.01% |
| 2026-08-05 | 0.01% |
| 2026-08-04 | 0.01% |
| 2026-08-03 | 0.01% |
| 2026-07-31 | 0.01% |
